Skip to main content Skip to navigation
Purified Mouse Anti-Human CD59
Purified Mouse Anti-Human CD59
Flow cytometric analysis of CD59 expression on glycosylphosphatidylinositol (GPI) anchor-defective mutant cell line (left panel) or K562 cell line (right panel). Cells were stained with either Purified Mouse IgG2a, κ Isotype Control (Cat. No. 555571; dashed line histograms) or Purified Mouse Anti-Human CD59 (Cat. No. 555761; solid line histograms), followed by FITC Goat Anti-Mouse IgG/IgM (Cat. No. 555988). Fluorescent histograms were derived from gated events with side and forward-light scattering characteristics of viable cells. Flow cytometry was performed on a BD FACSCan™ system.
Flow cytometric analysis of CD59 expression on glycosylphosphatidylinositol (GPI) anchor-defective mutant cell line (left panel) or K562 cell line (right panel). Cells were stained with either Purified Mouse IgG2a, κ Isotype Control (Cat. No. 555571; dashed line histograms) or Purified Mouse Anti-Human CD59 (Cat. No. 555761; solid line histograms), followed by FITC Goat Anti-Mouse IgG/IgM (Cat. No. 555988). Fluorescent histograms were derived from gated events with side and forward-light scattering characteristics of viable cells. Flow cytometry was performed on a BD FACSCan™ system.
Product Details
Down Arrow Up Arrow


BD Pharmingen™
HRF-20; MAC-inhibitory protein; MAC-IP; MACIF; MEM43; MIRL; Protectin; 1F5
Human (QC Testing), Rhesus,Cynomolgus,Baboon (Tested in Development)
Mouse IgG2a, κ
Human Erythrocytes
Flow cytometry (Routinely Tested), Immunofluorescence (Reported)
0.5 mg/ml
V S006
AB_396101
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. An isotype control should be used at the same concentration as the antibody of interest.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. Species cross-reactivity detected in product development may not have been confirmed on every format and/or application.
  5. Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
  6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
555761 Rev. 7
Antibody Details
Down Arrow Up Arrow
p282 (H19)

The p282 (HI9) monoclonal antibody specifically binds to CD59, a 19 kDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein, expressed on hematopoietic and non-hematopoietic cells. Because of its interaction with complement activated products, CD59 has been termed membrane-attack-complex-inhibitory factor (MACIF), homologus restriction factor (HRF20), membrane inhibitor of reactive lysis (MIRL) and Protectin. It inhibits the cytolytic activity of the complement system by binding to C8 and C9, thereby blocking the assembly of the membrane attack complex. CD59 also participates in spontaneous T-cell/erythrocyte adhesion, interacts with CD2, and plays a role in T-cell activation.

555761 Rev. 7
Format Details
Down Arrow Up Arrow
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
555761 Rev.7
Citations & References
Down Arrow Up Arrow

Development References (7)

  1. Barclay NA, Brown MH, Birkeland ML, et al, ed. The Leukocyte Antigen FactsBook. San Diego, CA: Academic Press; 1997.
  2. Davies A, Lachmann PJ. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res. 1993; 12(3):258-275. (Biology). View Reference
  3. Deckert M, Kubar J, Bernard A. CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation. J Immunol. 1992; 148(3):672-677. (Biology). View Reference
  4. Deckert M, Kubar J, Zoccola D, et al. CD59 molecule: a second ligand for CD2 in T cell adhesion. Eur J Immunol. 1992; 22(11):2943-2947. (Biology). View Reference
  5. Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997.
  6. Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995.
  7. Whitlow MB, Iida K, Stefanova I, Bernard A, Nussenzweig V. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol. 1990; 126(1):176-184. (Biology). View Reference
View All (7) View Less
555761 Rev. 7

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.